Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Cited by (1,009)

Items 301–400 of 1,009

1. Melanoma: What do all the mutations mean?
   Elizabeth J. Davis, Douglas Buckner Johnson, Jeffrey Alan Sosman, Sunandana Chandra · 2018 · Cancer
2. Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer
   Qianhui Xu, Shaohuai Chen, Yuanbo Hu, Wen Huang · 2021 · Frontiers in Immunology
3. Nanoparticle-enhanced radiotherapy synergizes with PD-L1 blockade to limit post-surgical cancer recurrence and metastasis
   Xin Guan, Liping Sun, Yuting Shen, Feng-Shan Jin, Xiao‐Wan Bo, Chunyan Zhu, Xiaoxia Han, Xiaolong Li, Yu Chen, Huixiong Xu et al. · 2022 · Nature Communications
4. Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
   Hao Chen, Wei Chong, Qian Wu, Yueliang Yao, Min Mao, Xin Wang · 2019 · Frontiers in Immunology
5. Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer
   Yilv Yan, Dongqing Sun, Junjie Hu, Yue Chen, Liangdong Sun, Huansha Yu, Yicheng Xiong, Zhida Huang, Haoran Xia, Xinsheng Zhu et al. · 2024 · Nature Genetics
6. Genomic Approaches to Understanding Response and Resistance to Immunotherapy
   David A. Braun, Kelly P. Burke, Eliezer M. Van Allen · 2016 · Clinical Cancer Research
7. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
   Derya Kabacaoğlu, Katrin J. Ciecielski, Dietrich Alexander Ruess, Hana Algül · 2018 · Frontiers in Immunology
8. Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
   Shixiang Wang, Li An Cowley, Xuesong Liu · 2019 · Molecules
9. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas
   Dodagatta-Marri, E., Meyer, D. S., Reeves, M. Q., Paniagua, R., To, M. D., Binnewies, M., Broz, M. L., Mori, H., Wu, D., Adoumie, M. et al. · 2019 · Journal for ImmunoTherapy of Cancer
10. Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment
    James L. Gulley, Jeffrey Schlom, Mary Helen Barcellos‐Hoff, Xiao‐Jing Wang, Joan Seoane, François Audhuy, Yan Lan, Isabelle Dussault, Aristidis Moustakas · 2021 · Molecular Oncology
11. Inhibitors of the PD-1 Pathway in Tumor Therapy
    Martin W. LaFleur, Yuki Muroyama, Charles G. Drake, Arlene H. Sharpe · 2018 · The Journal of Immunology
12. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
    Amy L. Shergold, Rhona Millar, Robert J. B. Nibbs · 2019 · Pharmacological Research
13. Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses
    Jay K. Mandula, Shiun Chang, Eslam T. Mohamed, Rachel Jimenez, Rosa A. Sierra-Mondragon, Darwin Chang, Alyssa Obermayer, Carlos Moran Segura, Satyajit Das, Julio Angel Vázquez-Martínez et al. · 2022 · Cancer Cell
14. The role of neoantigens in response to immune checkpoint blockade
    Nadeem Riaz, Luc G.T. Morris, Jonathan J. Havel, Vladimir Makarov, Alexis Desrichard, Timothy An-thy Chan · 2016 · International Immunology
15. Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade
    Sachet Ashok Shukla, Pavan Bachireddy, Bastian Schilling, Christina Galonska, Qian Zhan, Clyde Bango, Rupert Langer, Patrick C. Lee, Daniel Gusenleitner, Derin B. Keskin et al. · 2018 · Cell
16. Nano-puerarin regulates tumor microenvironment and facilitates chemo- and immunotherapy in murine triple negative breast cancer model
    Huan Xu, Mengying Hu, Mengrui Liu, Sai An, Kaiyun Guan, Menglin Wang, Lei Li, Jing Zhang, Jun Li, Leaf Huang · 2020 · Biomaterials
17. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma
    Douglas Buckner Johnson, Jennifer Bordeaux, Ju Young Kim, Christine Vaupel, David L. Rimm, Thai H. Ho, Richard Wayne Joseph, ADIL I. DAUD, Robert Martin Conry, Elizabeth Mary Gaughan et al. · 2018 · Clinical Cancer Research
18. Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment
    Zehang Jiang, Zhixian Liu, Mengyuan Li, Cai Chen, Xiaosheng Wang · 2019 · EBioMedicine
19. Discovering dominant tumor immune archetypes in a pan-cancer census
    Alexis J. Combes, Bushra Samad, Jessica L. Tsui, Nayvin W. Chew, Peter Yan, Gabriella C. Reeder, Divyashree Kushnoor, Alan S. Shen, Brittany R. Davidson, Andrea J. Barczak et al. · 2021 · Cell
20. Raman-guided subcellular pharmaco-metabolomics for metastatic melanoma cells
    Du, Jiajun, Su, Yapeng, Qian, Chenxi, Yuan, Dan, Miao, Kun, Lee, Dongkwan, Ng, Alphonsus H. C., Wijker, Reto S., Ribas, Antoni, Levine, Raphael D. et al. · 2020 · Nature Communications
21. Systems biology-based investigation of cooperating microRNAs as monotherapy or adjuvant therapy in cancer
    Xin Lai, Martin Eberhardt, Ulf Schmitz, Julio Vera · 2019 · Nucleic Acids Research
22. Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
    Michael Lawrence Dougan · 2017 · Frontiers in Immunology
23. Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)
    Nune Markosyan, Jinyang Li, Yu Huining Sun, Lee P. Richman, Jeffrey H. Lin, Fangxue Yan, Liz Quinones, Yogev Sela, Taiji Yamazoe, Naomi Gordon et al. · 2019 · Journal of Clinical Investigation
24. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition
    Girish S. Naik, Sushrut S. Waikar, Alistair E. W. Johnson, Elizabeth Iannotti Buchbinder, Rizwan Haq, Frank Stephen Hodi, Jonathan Daniel Schoenfeld, Patrick Alexander Ott · 2019 · Journal for ImmunoTherapy of Cancer
25. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
    Suzanne Thomas, Linta Kuncheria, Victoria Roulstone, Joan Kyula, David Mansfield, Praveen K. Bommareddy, Henry George Smith, Howard L. Kaufman, Kevin Joseph Harrington, Robert S. Coffin · 2019 · Journal for ImmunoTherapy of Cancer
26. Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy
    Evelien Schaafsma, Chloe M. Fugle, Xiaofeng Wang, Chao Cheng · 2021 · British Journal of Cancer
27. Copackaging photosensitizer and PD-L1 siRNA in a nucleic acid nanogel for synergistic cancer photoimmunotherapy
    Yuanyuan Guo, Qiushuang Zhang, Qiwen Zhu, Jing Gao, Xinyuan Zhu, Haijun Yu, Yuehua Li, Chuan Zhang · 2022 · Science Advances
28. Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically
    Shawn C. Chafe, Paul C. McDonald, Saeed Saberi, Oksana Nemirovsky, Geetha Venkateswaran, Samantha Burugu, Dongxia Gao, Alberto Delaidelli, Alastair Hugh Kyle, Jennifer H.E. Baker et al. · 2019 · Cancer Immunology Research
29. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
    Muhammad Umair Mushtaq, Athanasios Papadas, Adam C. Pagenkopf, Evan Flietner, Zachary T. Morrow, Sibgha Gull Chaudhary, Fotis A. Asimakopoulos · 2018 · Journal for ImmunoTherapy of Cancer
30. Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location
    Longhui Zhang, Yuetao Zhao, Ying Dai, Jianan Cheng, Zhihua Gong, Yi Feng, Chengdu Sun, Qingzhu Jia, Bo Zhu · 2018 · Frontiers in Immunology
31. Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis
    Mara Gagliardi, Diego Cotella, Claudio Santoro, Davide Corà, Nickolai A. Barlev, Mauro Piacentini, Marco Corazzari · 2019 · Cell Death and Disease
32. Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance
    Felicity Newell, Inês Pires da Silva, Peter A. Johansson, Alexander Maxwell Menzies, James S. Wilmott, Venkateswar Addala, Matteo Salvatore Carlino, Helen Rizos, Kátia Nones, Jarem J. Edwards et al. · 2021 · Cancer Cell
33. Biomarkers associated with checkpoint inhibitors
    Guillaume Manson, J. Norwood, Aurélien Marabelle, Holbrook E K Kohrt, Roch Houot · 2016 · Annals of Oncology
34. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
    Yoshio Nakamura, Shigehisa Kitano, Akira Takahashi, Arata Tsutsumida, Kenjiro Namikawa, Keiji Tanese, Takayuki Abe, Takeru Funakoshi, Noboru Yamamoto, Masayuki Amagai et al. · 2016 · Oncotarget
35. The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer
    André Steven, Barbara Seliger · 2018 · Breast Care
36. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
    Conway, Jake R., Kofman, Eric, Mo, Shirley S., Elmarakeby, Haitham, Van Allen, Eliezer · 2018 · Genome Medicine
37. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Benjamin Herzberg, Meghan J. Campo, Justin F. Gainor · 2016 · The Oncologist
38. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
    Douglas Buckner Johnson, Mellissa J. Nixon, Yu Wang, Daniel Y. Wang, Emily H. Castellanos, Monica Valeria Estrada, Paula I. González Ericsson, Candace H. Cote, Roberto Salgado, Violeta M. Sanchez et al. · 2018 · JCI Insight
39. Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state
    Daniela Cerezo‐Wallis, Marta Contreras-Alcalde, Kevin Troulé, Xavier Catena, Cynthia Mucientes, Tonantzin G. Calvo, Estela Cañón, Cristina Tejedo, Paula Comune Pennacchi, Sabrina A. Hogan et al. · 2020 · Nature Medicine
40. Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?
    Ferrara, Roberto, Mezquita, Laura, Auclin, Edouard, Chaput, Nathalie, Besse, Benjamin · 2017 · Cancer Treatment Reviews
41. Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
    Chung‐Han Lee, Roman Yelensky, Karin U. Jooss, Timothy An-thy Chan · 2018 · Trends in Immunology
42. Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation
    Zhi‐Ling Li, Hai‐Liang Zhang, Yun Huang, Jun-Hao Huang, Peng Sun, Ningning Zhou, Yuhong Chen, Jia Mai, Yan Wang, Yan Yu et al. · 2020 · Nature Communications
43. Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance
    Heng Lin, Ilona Kryczek, Shasha Li, Michael D. Green, Alicia Ali, Reema Hamasha, Shuang Wei, Linda Vatan, Wojciech Szeliga, Sara Grove et al. · 2021 · Cancer Cell
44. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
    Reinhard Dummer, Jan C. Brase, James Garrett, Catarina D. Campbell, Eduard Gasal, Matthew S. Squires, Daniel Gusenleitner, Mario Santinami, Victoria G. Atkinson, Mario Mandalà et al. · 2020 · The Lancet Oncology
45. Applications of single-cell and bulk RNA sequencing in onco-immunology
    Maria Kuksin, Daphné Morel, Marine Aglave, François‐Xavier Danlos, Aurélien Marabelle, Andrei Y. Zinovyev, Daniel Gautheret, Loïc Verlingue · 2021 · European Journal of Cancer
46. SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells
    Tom Li Stephen, Kyle K. Payne, Ricardo A. Chaurio, Michael J. Allegrezza, Hengrui Zhu, Jairo Pérez‐Sanz, Alfredo Perales‐Puchalt, Jenny M. Nguyen, Ana Vara-Ailor, Evgeniy B. Eruslanov et al. · 2017 · Immunity
47. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
    Karim Boudadi, Daniel L. Suzman, Valsamo Anagnostou, Wei Fu, Brandon S. Luber, Hao Wang, Noushin Niknafs, James Robert White, John L. Silberstein, Rana Sullivan et al. · 2018 · Oncotarget
48. Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
    Chunying Song, Marco Piva, Lu Sun, Aayoung Hong, Gatien Moriceau, Xiangju Kong, Hong Zhang, Shirley H. Lomeli, Jin Qian, Clarissa C. Yu et al. · 2017 · Cancer Discovery
49. Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Jie Bai, Zhitao Gao, Xiang Li, Liang Dong, Weidong Han, Jing Nie · 2017 · Oncotarget
50. Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
    Qingzhu Jia, Jun Wang, Ning He, Ji He, Bo Zhu · 2019 · JCI Insight
51. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer
    Kyung-Soo Kim, Seyeon Park, Sung Yong Park, Gamin Kim, Su Myeong Park, Jae-Won Cho, Dahee Kim, Young Min Park, Yoon Woo Koh, Hye Ryun Kim et al. · 2020 · Genome Medicine
52. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group
    Leticia De Mattos‐Arruda, Miguél Vázquez, Francesca Finotello, Rosalba Lepore, E. Porta, Jasreet Hundal, Pep Amengual-Rigo, Charlotte K.Y. Ng, Alfonso Valencia, Jorge Carrillo et al. · 2020 · Annals of Oncology
53. Synthetic lethality-mediated precision oncology via the tumor transcriptome
    Joo Sang Lee, Nishanth Ulhas Nair, Gal Dinstag, Lesley M. Chapman, Youngmin Chung, Kun Wang, Sanju Sinha, Hongui Cha, Dasol Kim, Alexander V. Schperberg et al. · 2021 · Cell
54. MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
    Julia Reinhardt, Jennifer Landsberg, Jonathan Leo Schmid-Burgk, Bartomeu Bibiloni Ramis, Tobias Bald, Nicole Glodde, Dorys Lopez-Ramos, Arabella Young, Shin Foong Ngiow, Daniel Nettersheim et al. · 2017 · Cancer Research
55. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
    Jong Yeob Kim, Andreas Kronbichler, Michael Eisenhut, Sung Hwi Hong, Hans J. van der Vliet, Jeonghyun Kang, Jae Il Shin, Gabriele Gamerith · 2019 · Cancers
56. Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy
    Yi Sun, Wei Chen, Robert J. Torphy, Sheng Yao, Gefeng Zhu, Ronggui Lin, Roberta Lugano, Emily N. Miller, Yuki Fujiwara, Li Bian et al. · 2021 · Science Translational Medicine
57. The role of RNA methylation in tumor immunity and its potential in immunotherapy
    Yan Li, Haoer Jin, Qingling Li, Liangrong Shi, Yitao Mao, Luqing Zhao · 2024 · Molecular Cancer
58. TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy
    Yemsratch T. Akalu, Carla Vanina Rothlin, Sourav Ghosh · 2017 · Immunological Reviews
59. Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy
    Sun-Hee Kim, Jason Roszik, Elizabeth Ann Grimm, Sühendan Ekmekçioglu · 2018 · Frontiers in Oncology
60. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
    Zi Yin, Min Yu, Tingting Ma, Chuanzhao Zhang, Shanzhou� Huang, Mohammad Reza Karimzadeh, Amir Abbas Momtazi‐Borojeni, Sheng Chen · 2021 · Journal for ImmunoTherapy of Cancer
61. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications
    Miguel A. Martín-Serrano, Benjamin Kepecs, Miguel Torres‐Martín, Emily R. Bramel, Philipp Konstantin Haber, Elliot Merritt, Alexander Rialdi, Nesteene Joy Param, Miho Maeda, Katherine E. Lindblad et al. · 2022 · Gut
62. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
    Marcel A. Deken, Jules Gadiot, Ekaterina S. Jordanova, Ruben Lacroix, Melissa M. J. van Gool, Paula Kroon, Cristina Pineda, Marnix H. Geukes Foppen, Richard A. Scolyer, Ji‐Ying Song et al. · 2016 · OncoImmunology
63. Dietary Lactobacillus -Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy
    Hirotaka Kawanabe-Matsuda, Kazuyoshi Takeda, Marie Nakamura, Seiya Makino, Takahiro Karasaki, Kazuhiro Kakimi, Megumi Nishimukai, Tatsukuni Ohno, Jumpei Omi, Kuniyuki Kano et al. · 2022 · Cancer Discovery
64. Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance
    Orgaz, Jose L., Crosas-Molist, Eva, Sadok, Amine, Perdrix-Rosell, Anna, Maiques, Oscar, Rodriguez-Hernandez, Irene, Monger, Jo, Mele, Silvia, Georgouli, Mirella, Bridgeman, Victoria et al. · 2020 · Cancer Cell
65. Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
    Shelly Kalaora, Joo Sang Lee, Eilon Barnea, Ronen Levy, Polina Greenberg, Michal Alon, Gal Yagel, Gitit Bar Eli, Roni Oren, Aviyah Peri et al. · 2020 · Nature Communications
66. CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer
    Lin, Anqi, Qi, Chang, Wei, Ting, Li, Mengyao, Cheng, Quan, Liu, Zaoqu, Luo, Peng, Zhang, Jian · 2022 · Briefings in Bioinformatics
67. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
    Harriet M. Kluger, Christopher R. Zito, Gabriela Turcu, Marina K. Baine, Hongyi Zhang, Adebowale Adeniran, Mario Sznol, David L. Rimm, Yuval Kluger, Lieping Chen et al. · 2017 · Clinical Cancer Research
68. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
    Fang, Douglas D., Tang, Qiuqiong, Kong, Yanhui, Wang, Qixin, Gu, Jiaxing, Fang, Xu, Zou, Peng, Rong, Tao, Wang, Jingwen, Yang, Dajun et al. · 2019 · Journal for ImmunoTherapy of Cancer
69. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer
    David Liu, Philip H. Abbosh, Daniel Keliher, Brendan Michael Reardon, Diana Miao, Kent William Mouw, Amaro N Taylor-Weiner, Stephanie A. M. Wankowicz, G. Celine Han, Min Yuen Teo et al. · 2017 · Nature Communications
70. PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
    Menglei Jin, Jun Fang, Junwen Peng, Xintian Wang, Ping Xing, Kunpeng Jia, Jianming Hu, Danting Wang, Yuxin Ding, Xinyu Wang et al. · 2024 · Molecular Cancer
71. Immune Checkpoint in Glioblastoma: Promising and Challenging
    Jing Huang, Fangkun Liu, Zhixiong Liu, Hui Tang, Haishan Wu, Qian-Ni Gong, Jindong Chen · 2017 · Frontiers in Pharmacology
72. Starvation and Pseudo-Starvation as Drivers of Cancer Metastasis through Translation Reprogramming
    Custodia García‐Jiménez, Colin R. Goding · 2018 · Cell Metabolism
73. Meeting the Challenge of Targeting Cancer Stem Cells
    Alice Turdo, Veronica Veschi, Miriam Gaggianesi, Aurora Chinnici, Paola Bianca, Matilde Todaro, Giorgio Stassi · 2019 · Frontiers in Cell and Developmental Biology
74. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints
    Yongshu Li, Fangfei Li, Feng Jiang, Xiaoqing Lv, Rongjiang Zhang, Aiping Lü, Ge Zhang · 2016 · International Journal of Molecular Sciences
75. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
    Dmitriy Zamarin, Jacob M. Ricca, Svetlana Sadekova, Anton Oseledchyk, Ying Yu, Wendy M. Blumenschein, Jerelyn Wong, Mathieu Gigoux, Taha Merghoub, Jedd D. Wolchok · 2018 · Journal of Clinical Investigation
76. NK Cell Dysfunction and Checkpoint Immunotherapy
    Jiacheng Bi, Zhigang Tian · 2019 · Frontiers in Immunology
77. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
    Carl Morrison, Sarabjot Pabla, Jeffrey M. Conroy, Mary Nesline, Sean T. Glenn, Devin C. Dressman, Antonios Papanicolau‐Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo et al. · 2018 · Journal for ImmunoTherapy of Cancer
78. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
    Qiaohong Wang, Xia Wu · 2017 · International Immunopharmacology
79. The molecular feature of macrophages in tumor immune microenvironment of glioma patients
    Hao Zhang, Yue‐Bei Luo, Wantao Wu, Liyang Zhang, Zeyu Wang, Ziyu Dai, Songshan Feng, Hui Cao, Quan Cheng, Zhixiong Liu · 2021 · Computational and Structural Biotechnology Journal
80. Characterization of cancer-related fibroblasts (CAF) in hepatocellular carcinoma and construction of CAF-based risk signature based on single-cell RNA-seq and bulk RNA-seq data
    Lianghe Yu, Ningjia Shen, Yan Shi, Xintong Shi, Xiaohui Fu, Shuang Li, Bin Zhu, Wenlong Yu, Yongjie Jessica Zhang · 2022 · Frontiers in Immunology
81. Persistent mutation burden drives sustained anti-tumor immune responses
    Noushin Niknafs, Archana Balan, Christopher Cherry, Karlijn Hummelink, Kim Monkhorst, Xiaoshan M. Shao, Zineb Belcaid, Kristen Ashley Marrone, Joseph Christopher Murray, Kellie Nicole Smith et al. · 2023 · Nature Medicine
82. Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
    Haber, Philipp K., Castet, Florian, Torres-Martin, Miguel, Andreu-Oller, Carmen, Puigvehí, Marc, Miho, Maeda, Radu, Pompilia, Dufour, Jean-Francois, Verslype, Chris, Zimpel, Carolin et al. · 2023 · Gastroenterology
83. Hallmarks of Resistance to Immune-Checkpoint Inhibitors
    Maria Karasarides, Alexandria P. Cogdill, Paul B. Robbins, Michaela Bowden, Elizabeth M. Burton, Lisa Helene Butterfield, Alessandra Cesano, Christian Hammer, Cara Haymaker, Christine E. Horak et al. · 2022 · Cancer Immunology Research
84. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2
    Linh T. Nguyen, Samuel David Saibil, Valentin Sotov, Michael X. Le, Leila Khoja, Danny Ghazarian, Luisa Bonilla, Habeeb Majeed, David Hogg, Anthony Michael Joshua et al. · 2019 · Cancer Immunology Immunotherapy
85. Preclinical murine tumor models: A structural and functional perspective
    Marion V. Guérin, Veronica Finisguerra, Benoit J. Van den Eynde, Nadège Bercovici, Alain Trautmann · 2020 · eLife
86. Tumor Plasticity and Resistance to Immunotherapy
    Lucas A. Horn, Kristen Fousek, Claudia Palena · 2020 · Trends in cancer
87. Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma
    Nan Zhang, Hao Zhang, Wantao Wu, Ran Zhou, Shuyu Li, Zeyu Wang, Ziyu Dai, Liyang Zhang, Fangkun Liu, Zaoqu Liu et al. · 2022 · Theranostics
88. Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma
    Hirokazu Sadahiro, Kyung‐Don Kang, Justin Tyler Gibson, Mutsuko Minata, Hai Yu, Junfeng Shi, Rishi Raj Chhipa, Zhihong Chen, Songjian Lu, Yannick Simoni et al. · 2018 · Cancer Research
89. Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes
    Lien Van Hoecke, Sandra Van Lint, Kenny Roose, Alexander Van Parys, Peter Vandenabeele, Johan Grooten, Jan H. Tavernier, Stefaan De Koker, Xavier Saelens · 2018 · Nature Communications
90. Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
    Marie-Léa Gauci, Émilie Lanoy, Stéphane Champiat, Caroline Caramella, Samy Ammari, Sandrine Aspeslagh, Andréa Varga, Capucine Baldini, Rastilav Bahleda, Anas Gazzah et al. · 2018 · Clinical Cancer Research
91. Identification of a prognostic immune signature for cervical cancer to predict survival and response to immune checkpoint inhibitors
    Si Yang, Ying Wu, Yujiao Deng, Linghui Zhou, Pengtao Yang, Yi Zheng, Dai Zhang, Zhen Zhai, Na Li, Qian Hao et al. · 2019 · OncoImmunology
92. The emergence of drug resistance to targeted cancer therapies: Clinical evidence
    Ana Bela Sarmento‐Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, Thomas Efferth, Ioannis P. Trougakos · 2019 · Drug Resistance Updates
93. Direct and Indirect Regulators of Epithelial–Mesenchymal Transition–Mediated Immunosuppression in Breast Carcinomas
    Anushka Dongre, Mohammad Rashidian, Elinor Ng Eaton, Ferenc Reinhardt, Prathapan Thiru, Maria Zagorulya, Sunita Nepal, Tuba Banaz, Anna Martner, Stefani Spranger et al. · 2020 · Cancer Discovery
94. Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma
    Winnie S. Liang, William P.D. Hendricks, Jeffrey Kiefer, Jessica E. Schmidt, Shobana Sekar, John David Carpten, David Wesley Craig, Jonathan R. Adkins, Lori Cuyugan, Zarko Manojlovic et al. · 2017 · Genome Research
95. Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes
    Zaitsev, Aleksandr, Chelushkin, Maksim, Dyikanov, Daniiar, Cheremushkin, Ilya, Shpak, Boris, Nomie, Krystle, Zyrin, Vladimir, Nuzhdina, Ekaterina, Lozinsky, Yaroslav, Zotova, Anastasia et al. · 2022 · Cancer Cell
96. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies
    Anna Rachel Minchom, Caterina Aversa, Juanita Suzanne Lopez · 2018 · Therapeutic Advances in Medical Oncology
97. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients
    Dedong Cao, Huilin Xu, Ximing Xu, Tao Guo, Wei Ge · 2019 · OncoImmunology
98. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads
    Danielle M. Lussier, Elise Alspach, Jeffrey P. Ward, Alexander P. Miceli, Daniele Runci, J. Michael White, Cedric Mpoy, Cora D. Arthur, Heather N. Kohlmiller, Tyler Jacks et al. · 2021 · Proceedings of the National Academy of Sciences
99. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer
    Hang Zheng, Heshu Liu, Huayu Li, Weidong Dou, Jingui Wang, Junling Zhang, Tao Liu, Yingchao Wu, Yucun Liu, Xin Wang · 2022 · Stem Cell Research & Therapy
100. Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications
     Qiurong Yang, Jing Bo Xu, Jianmei Gu, Hui Shi, Jiayin Zhang, Jianye Zhang, Zhe‐Sheng Chen, Xinjian Fang, Taofeng Zhu, Xu Zhang · 2022 · Advanced Science